Phaseline

Companies › Ascendis Pharma

Ascendis Pharma: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 3; Metabolic and endocrine, Other; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Palopegteriparatide
Parathyroid hormone receptor agonist
PTH1RPhase 3HypoparathyroidismAug 2027
Lonapegsomatropin
Growth hormone receptor agonist
GHRPhase 3Turner SyndromeFeb 2028
Navepegritide (TransCon CNP)–Phase 2AchondroplasiaSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07706764PalopegteriparatidePhase 3HypoparathyroidismMetabolic and endocrineAug 2027
NCT06732895Navepegritide (TransCon CNP)Phase 2AchondroplasiaOtherSep 2027
NCT06079398Navepegritide (TransCon CNP)Phase 2AchondroplasiaOtherDec 2027
NCT07221851LonapegsomatropinPhase 3Turner SyndromeMetabolic and endocrineFeb 2028

From the company's SEC filings

Cash of 616m EUR on 2025-12-31; operating cash flow positive

Complete response letters from FDA

Specialist investors

Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PTH1R (1) GHR (1)

Companies with the same targets

Ascendis Pharma Bone Diseases AstraZeneca Novo Nordisk Changchun GeneScience Pharmaceutical Ascendis Pharma Growth Disorders Ascendis Pharma Endocrinology Division

Companies built like this

Ascendis Pharma Bone Diseases BioXTek HealthTech Wound Care PolarityTE Royal Biologics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.